skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: assunto: Medical Sciences remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection
Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection
Material Type:
Artigo 		Adicionar ao Meu Espaço

Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection

SMALLEY, Stephen R ; BENEDETTI, Jacqueline K ; STEMMERMANN, Grant N ; BLANKE, Charles D ; MACDONALD, John S ; HALLER, Daniel G ; HUNDAHL, Scott A ; ESTES, Norman C ; AJANI, Jaffer A ; GUNDERSON, Leonard L ; GOLDMAN, Bryan ; MARTENSON, James A ; JESSUP, J. Milburn

Journal of clinical oncology, 2012-07, Vol.30 (19), p.2327-2333 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
2
Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

DEMETRI, George D ; YANFENG WANG ; WEHRLE, Elisabeth ; RACINE, Amy ; NIKOLOVA, Zariana ; BLANKE, Charles D ; JOENSUU, Heikki ; VON MEHREN, Margaret

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3141-3147 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
3
Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence
Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence
Material Type:
Artigo 		Adicionar ao Meu Espaço

Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence

McCarter, Martin D., MD, FACS ; Antonescu, Cristina R., MD ; Ballman, Karla V., PhD ; Maki, Robert G., MD, PhD ; Pisters, Peter W.T., MD, FACS ; Demetri, George D., MD ; Blanke, Charles D., MD ; von Mehren, Margaret, MD ; Brennan, Murray F., MD, FACS ; McCall, Linda, MS ; Ota, David M., MD, FACS ; DeMatteo, Ronald P., MD, FACS

Journal of the American College of Surgeons, 2012-07, Vol.215 (1), p.53-59 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por
4
Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

BLANKE, Charles D ; DEMETRI, George D ; WEHRE, Elisabeth ; NIKOLOVA, Zariana ; JOENSUU, Heikki ; VON MEHREN, Margaret ; HEINRICH, Michael C ; EISENBERG, Burton ; FLETCHER, Jonathan A ; CORLESS, Christopher L ; FLETCHER, Christopher D. M ; ROBERTS, Peter J ; HEINZ, Daniela

Journal of clinical oncology, 2008-02, Vol.26 (4), p.620-625 [Periódico revisado por pares]

Baltimore, MD: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
5
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

PHILIP, Philip A ; BENEDETTI, Jacqueline ; KHORANA, Alok A ; GOLDMAN, Bryan ; FENOGLIO-PREISER, Cecilia M ; ABBRUZZESE, James L ; BLANKE, Charles D ; CORLESS, Christopher L ; WONG, Ralph ; O'REILLY, Eileen M ; FLYNN, Patrick J ; ROWLAND, Kendrith M ; ATKINS, James N ; MIRTSCHING, Barry C ; RIVKIN, Saul E

Journal of clinical oncology, 2010-08, Vol.28 (22), p.3605-3610 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
6
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

DeMatteo, Ronald P, Prof ; Ballman, Karla V, PhD ; Antonescu, Cristina R, MD ; Maki, Robert G, MD ; Pisters, Peter WT, Prof ; Demetri, George D, MD ; Blackstein, Martin E, MD ; Blanke, Charles D, Prof ; von Mehren, Margaret, MD ; Brennan, Murray F, Prof ; Patel, Shreyaskumar, Prof ; McCarter, Martin D, MD ; Polikoff, Jonathan A, MD ; Tan, Benjamin R, MD ; Owzar, Kouros, PhD

The Lancet (British edition), 2009-03, Vol.373 (9669), p.1097-1104 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

BLANKE, Charles D ; RANKIN, Cathryn ; TANAKA, Michael ; HECHT, J. Randolph ; HEINRICH, Michael C ; FLETCHER, Christopher D. M ; CROWLEY, John J ; BORDEN, Ernest C ; DEMETRI, George D ; RYAN, Christopher W ; VON MEHREN, Margaret ; BENJAMIN, Robert S ; RAYMOND, A. Kevin ; BRAMWELL, Vivien H. C ; BAKER, Laurence H ; MAKI, Robert G

Journal of clinical oncology, 2008-02, Vol.26 (4), p.626-632 [Periódico revisado por pares]

Baltimore, MD: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
8
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Material Type:
Artigo 		Adicionar ao Meu Espaço

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

HEINRICH, Michael C ; OWZAR, Kouros ; BENJAMIN, Robert S ; BRAMWELL, Vivien H ; DEMETRI, George D ; BERTAGNOLLI, Monica M ; FLETCHER, Jonathan A ; CORLESS, Christopher L ; HOLLIS, Donna ; BORDEN, Ernest C ; FLETCHER, Christopher D. M ; RYAN, Christopher W ; VON MEHREN, Margaret ; BLANKE, Charles D ; RANKIN, Cathryn

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5360-5367 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
9
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

Iqbal, S. ; Goldman, B. ; Fenoglio-Preiser, C.M. ; Lenz, H.J. ; Zhang, W. ; Danenberg, K.D. ; Shibata, S.I. ; Blanke, C.D.

Annals of oncology, 2011-12, Vol.22 (12), p.2610-2615 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

EL-KHOUEIRY, A. B ; RANKIN, C ; SIEGEL, A. B ; IQBAL, S ; GONG, I.-Y ; MICETICH, K. C ; KAYALEH, O. R ; LENZ, H.-J ; BLANKE, C. D

British journal of cancer, 2014-02, Vol.110 (4), p.882-887 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (66)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (66)
  2. Anais de Congresso  (1)
  3. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1995  (4)
  2. 1995Até1999  (6)
  3. 2000Até2003  (22)
  4. 2004Até2008  (11)
  5. Após 2008  (25)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.